FDA works closely with industry, health care providers, and patients to prevent and mitigate shortages of medically necessary medicines the Drug Shortage Program DSP at FDA considers to be used to treat or prevent a serious disease or medical condition for which there is no alternative medicine available in adequate supply <a href=https://alevitra.mom>levitra en horaire</a> Standards of care for patients at risk for or with CIPN are based on a thorough assessment of sensory symptoms such as pain; diminished or heightened sensations; cutaneous hypersensitivity of the hands and feet allodynia or hyperalgesia; the ability to discriminate sensations of cold, sharp, and dull; and absence of the ability to detect stimuli numbness, response to vibration, and positioning of distal areas such as the toes and fingers